Unity Biotechnology Inc
Company Profile
Business description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Contact
285 East Grand Avenue
South San FranciscoCA94080
USAT: +1 650 416-1192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
stocks
10 of the cheapest global companies with wide moats
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,114.57 | 40.59 | 0.50% |
| DAX 40 | 23,393.23 | 238.66 | 1.03% |
| Dow JONES (US) | 41,472.25 | 369.38 | -0.88% |
| FTSE 100 | 8,705.23 | 24.94 | 0.29% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,498.52 | 310.15 | -1.74% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 89.29 | -0.73% |
| S&P 500 | 5,607.63 | 67.49 | -1.19% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |